Statement on EU India and EU Mercosur Free-Trade Negotiations

Medicines pay-for-delay back under the microscope

Transparency of European Medicines Regulation


Increasing Calls Within the EU for New Models of Medical Innovation

EMA Talks the ‘Conflicts of Interest’ Talk, but Will it Walk the Walk?

EU Citizens Get a Voice in Pharmacovigilance

Как распознавать продвижение лекарств и как к нему относиться: Практическое руководство

Comprender la promoción farmacéutica y responder a ella: Una guía práctica

Understanding & Responding to Pharmaceutical Promotion: A Practical Guide

WHO Should Refocus its Efforts on Wider Public Health Threats

Direct Patient Reporting of Adverse Drug Reactions

HAI Europe is Granted Full Membership by the European Medicines Agency


European Medicines’ Policy Where it Belongs

Unbiased medicines’ information: European best practices

Wyzwanie dla niezależnej informacji: dyrektywa w sprawie informowania pacjentów

Rozumienie promocji leków i reagowanie na nia: Praktyczny przewodnik 2009

Understanding and Responding to Pharmaceutical Promotion: A Practical Guide

The Tide is Turning Against Pharmaceutical Ads

Protect Legitimate Trade in Essential Medicines

DG Competition Pharmaceutical Sector Inquiry – Final Report

HAI Requests Government Documents on Generic Medicines Seizures

Release of Generic ARV Medicines by Dutch Customs Authorities


HAI Statutenwijziging (HAI Constitution – Dutch)

HAI Constitution


Fast, Furious, and Flexible


East Africa Community and a 10% Tax on Medicines